ZA966934B - Prostaglandin derivatives. - Google Patents
Prostaglandin derivatives.Info
- Publication number
- ZA966934B ZA966934B ZA9606934A ZA966934A ZA966934B ZA 966934 B ZA966934 B ZA 966934B ZA 9606934 A ZA9606934 A ZA 9606934A ZA 966934 A ZA966934 A ZA 966934A ZA 966934 B ZA966934 B ZA 966934B
- Authority
- ZA
- South Africa
- Prior art keywords
- ch2ch2
- formula
- blood flow
- prostaglandin derivatives
- prostaglandin
- Prior art date
Links
- 150000003180 prostaglandins Chemical class 0.000 title 1
- 230000017531 blood circulation Effects 0.000 abstract 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 208000004210 Pressure Ulcer Diseases 0.000 abstract 1
- -1 Prostaglandin E1 ester Chemical class 0.000 abstract 1
- 206010040943 Skin Ulcer Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229960000711 alprostadil Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- 231100000019 skin ulcer Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Biotechnology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23076395 | 1995-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA966934B true ZA966934B (en) | 1997-02-19 |
Family
ID=16912888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9606934A ZA966934B (en) | 1995-08-16 | 1996-08-15 | Prostaglandin derivatives. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5690957A (xx) |
| EP (1) | EP0758645B1 (xx) |
| KR (1) | KR100225689B1 (xx) |
| CN (1) | CN1058706C (xx) |
| AT (1) | ATE185559T1 (xx) |
| AU (1) | AU708905B2 (xx) |
| CA (1) | CA2183486C (xx) |
| DE (1) | DE69604631T2 (xx) |
| DK (1) | DK0758645T3 (xx) |
| ES (1) | ES2140032T3 (xx) |
| GR (1) | GR3032274T3 (xx) |
| HU (1) | HUP9602262A3 (xx) |
| MX (1) | MX9603452A (xx) |
| NO (1) | NO309086B1 (xx) |
| TW (1) | TW367324B (xx) |
| ZA (1) | ZA966934B (xx) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006113310A2 (en) * | 2005-04-13 | 2006-10-26 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising prostaglandin derivatives |
| CN1813679A (zh) * | 2005-11-30 | 2006-08-09 | 上海医药(集团)有限公司 | 一种紫杉烷脂质体冻干组合物及其制备方法 |
| US8916206B2 (en) * | 2005-12-26 | 2014-12-23 | Ltt Bio-Pharma Co., Ltd. | Nanoparticles containing water-soluble non-peptide low-molecular weight drug |
| CN103755737A (zh) * | 2006-02-07 | 2014-04-30 | 株式会社·R-技术上野 | 用于制备前列腺素衍生物的方法 |
| EP2156848A4 (en) * | 2007-05-14 | 2012-11-28 | Ltt Bio Pharma Co Ltd | NANOPARTICLE CONTAINING A LOW MOLECULAR WEIGHT DRUG HAVING A NEGATIVELY PROLONGED RELEASE GROUP |
| ITCA20080017A1 (it) * | 2008-07-31 | 2010-02-01 | Giuseppe Brotzu | Farmaco a base di liposomi di fosfatidilcolina trasportanti una prostaglandina e1 legata alla alfa-ciclodestrina per il trattamento delle microngiopatie diabetiche e altre patologie vascolari. |
| WO2010058669A1 (ja) * | 2008-11-18 | 2010-05-27 | 株式会社Ｌｔｔバイオファーマ | 新規プロスタグランジンｅ１誘導体及びそれを封入するナノ粒子 |
| US8569279B2 (en) | 2009-05-27 | 2013-10-29 | Sucampo Ag | Method for modulating claudin mediated functions |
| KR20120031954A (ko) * | 2009-05-27 | 2012-04-04 | 수캄포 아게 | 클라우딘 매개 기능을 조정하고 피부 장애를 치료하는데 사용하기 위한 프로스타글란딘 유도체를 포함하는 제약 조성물 |
| CN102028696B (zh) * | 2009-09-24 | 2013-02-13 | 上海天伟生物制药有限公司 | 一种前列腺素类化合物的用途 |
| CN101912363A (zh) * | 2010-07-29 | 2010-12-15 | 蔡海德 | 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4054736A (en) * | 1970-06-10 | 1977-10-18 | Ono Pharmaceutical Co., Ltd. | Clathrate compounds of prostaglandins or their analogues with cyclodextrin |
| JPS59206349A (ja) * | 1983-05-10 | 1984-11-22 | Green Cross Corp:The | プロスタグランジンｅ↓１誘導体 |
-
1996
- 1996-08-07 TW TW085109565A patent/TW367324B/zh active
- 1996-08-13 KR KR1019960033503A patent/KR100225689B1/ko not_active IP Right Cessation
- 1996-08-14 US US08/699,700 patent/US5690957A/en not_active Expired - Fee Related
- 1996-08-15 AU AU62105/96A patent/AU708905B2/en not_active Ceased
- 1996-08-15 ZA ZA9606934A patent/ZA966934B/xx unknown
- 1996-08-15 HU HU9602262A patent/HUP9602262A3/hu unknown
- 1996-08-15 EP EP96305966A patent/EP0758645B1/en not_active Expired - Lifetime
- 1996-08-15 DK DK96305966T patent/DK0758645T3/da active
- 1996-08-15 DE DE69604631T patent/DE69604631T2/de not_active Expired - Fee Related
- 1996-08-15 AT AT96305966T patent/ATE185559T1/de not_active IP Right Cessation
- 1996-08-15 ES ES96305966T patent/ES2140032T3/es not_active Expired - Lifetime
- 1996-08-15 NO NO963408A patent/NO309086B1/no not_active IP Right Cessation
- 1996-08-16 CA CA002183486A patent/CA2183486C/en not_active Expired - Fee Related
- 1996-08-16 CN CN96113280A patent/CN1058706C/zh not_active Expired - Fee Related
- 1996-08-16 MX MX9603452A patent/MX9603452A/es unknown
-
1999
- 1999-12-28 GR GR990403361T patent/GR3032274T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2140032T3 (es) | 2000-02-16 |
| DE69604631T2 (de) | 2000-02-17 |
| ATE185559T1 (de) | 1999-10-15 |
| KR100225689B1 (ko) | 1999-10-15 |
| KR970010742A (ko) | 1997-03-27 |
| TW367324B (en) | 1999-08-21 |
| NO309086B1 (no) | 2000-12-11 |
| DK0758645T3 (da) | 1999-12-27 |
| NO963408D0 (no) | 1996-08-15 |
| CA2183486A1 (en) | 1997-02-17 |
| MX9603452A (es) | 1997-03-29 |
| NO963408L (no) | 1997-02-17 |
| AU6210596A (en) | 1997-02-20 |
| HUP9602262A3 (en) | 1997-08-28 |
| DE69604631D1 (de) | 1999-11-18 |
| EP0758645A1 (en) | 1997-02-19 |
| AU708905B2 (en) | 1999-08-12 |
| EP0758645B1 (en) | 1999-10-13 |
| HUP9602262A2 (en) | 1997-05-28 |
| CN1151398A (zh) | 1997-06-11 |
| HU9602262D0 (en) | 1996-10-28 |
| CN1058706C (zh) | 2000-11-22 |
| CA2183486C (en) | 2002-03-26 |
| US5690957A (en) | 1997-11-25 |
| GR3032274T3 (en) | 2000-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2259621A1 (en) | Isocoumarin derivatives and their use in medicines | |
| HU9600834D0 (en) | Quinazoline derivatives | |
| IL112572A0 (en) | Dexanabinol derivatives and their use as nmda blocking pharmaceutical compositions | |
| ATE157346T1 (de) | Hexahydronapththalinesterderivate, ihre herstellung und ihre therapeutischen verwendungen | |
| HU9602262D0 (en) | Prostaglandin derivatives | |
| KR890003382A (ko) | 항 비루스성 화합물 | |
| TNSN87012A1 (fr) | Nouveaux derives de dihydrobenzofuranne - et de chromane - carboxamides, leurs procedes de preparation et leur utilisation comme neuroleptiques | |
| MA23639A1 (fr) | Derives pyrrocarbazole, leur preparation, les compositions pharmaceutiques les contenant, leur utilisation dans le traitement des tumeurs malignes. | |
| DE69312567D1 (de) | 2-Formylpyridin-Thiosemicarbazonderivate, ihre Herstellung und ihre Verwendung als Antitumor Mittel | |
| AU3453493A (en) | Pharmaceutical preparation based on rhamnolipid against dermatological diseases, e.g. papilloma virus infections | |
| DE60019086D1 (de) | Zusammensetzungen zur behandlung von hautkrankheiten | |
| BR9503572A (pt) | Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença | |
| GR3033195T3 (en) | Prostaglandin derivatives | |
| MA26725A1 (fr) | Derives de resorcinol, compositions pharmaceutiques les contenant et procede pour leur preparation | |
| ITMI922742A1 (it) | Composti ad attivita' terapeutica utili per il trattamento di malattie connesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono. | |
| ZA939153B (en) | Use of idazoxan and its derivatives for the preparation of a medicinal product intended for the treatment of parkinson's disease and its development | |
| NZ246598A (en) | Trazodone derivatives; compounds and preparation, pharmaceutical compositions; intermediate compounds | |
| ES2096208T3 (es) | Derivados de octahidronaftaleno oxima para la inhibicion de la biosintesis de colesterol, su preparacion y utilizacion. | |
| AU1645897A (en) | Benzopyran derivative and use of said benzopyran derivative for treating heart disease | |
| MA26626A1 (fr) | Derives de 2"-desoxy-hygromycine a nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| ES2134441T3 (es) | Benzonitrilos terapeuticos. | |
| DE69330269D1 (de) | Benzopyran-derivate, deren herstellung sowie diese als aktive bestandteile enthaltende arzneimittel | |
| FR2414333A2 (fr) | Composition pharmaceutique contenant comme ingredient actif la d-2-bromo 6-methyl-8b-(morpholinocarbonyoxymethyl)-ergoline, utile notamment pour le traitement de l'asthme | |
| EP0178176A3 (en) | Tetrahydro-1,2,4-oxadiazine-5-thione derivatives | |
| AU1665397A (en) | 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses |